21 results on '"Majeti, Ravindra"'
Search Results
2. Mesenchymal Stromal Cells Rescue Hypoxia-Induced Survival Defect in Ex Vivo Acute Myeloid Leukemia Cell Cultures
- Author
-
Martinez-Krams, Daniel and Majeti, Ravindra
- Subjects
Acute myeloid leukemia ,Microenvironment ,Drug discovery ,Niche ,Cytokines ,Stem cells ,Hypoxia ,Biology ,Conditioned media ,Personalized medicine ,Cancer ,Hematopoiesis - Abstract
Acute myeloid leukemia (AML) is an aggressive cancer characterized by the clonal accumulation of immature blood cells. The cancer stem cell model hypothesizes that healthy hematopoietic stem cells (HSCs), which populate the entire blood compartment, acquire lesions over time and become leukemia stem cells (LSCs). These mutant cells are responsible for disease progression and act as a reservoir of cancer-forming cells following chemotherapy, causing relapse. In healthy hematopoiesis, mesenchymal stromal cells (MSCs) in the oxygen-poor bone marrow microenvironment are the niche for HSCs, providing factors to maintain and regulate self-renewal and multipotency. Current efforts seek to understand the role of the niche in aberrant hematopoiesis. While efforts to replicate human disease are aided by the in vitro study of primary AML patient sample cells (APSCs), these studies do not typically recapitulate the presence of MSCs or the hypoxic conditions of the niche. I found that hypoxia decreases APSC growth, but this defect can be rescued in a non-contact-dependent manner by co-culture of APSC with MSC or culture of APSC in MSC-conditioned media (CM). Cytokine detection analysis showed that MSC-CM contained high levels of cytokines whose transcripts are also highly expressed in primary MSCs from healthy donors. Although no singular tested cytokine was necessary for APSC survival, I determined that the expression of cytokines and receptors can independently cluster healthy and leukemic cell subsets. Therefore, cytokine combinations may contribute to APSC survival. Collectively, these results show that MSCs are sufficient to enhance APSC survival in physiologic hypoxia. The niche-like ex vivo model I established will enable the translation of laboratory findings into clinical applications.
- Published
- 2022
- Full Text
- View/download PDF
3. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia
- Author
-
Chan, Steven M. and Majeti, Ravindra
- Published
- 2013
- Full Text
- View/download PDF
4. Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia.
- Author
-
Benard, Brooks A., Leak, Logan B., Azizi, Armon, Thomas, Daniel, Gentles, Andrew J., and Majeti, Ravindra
- Subjects
ACUTE myeloid leukemia ,TREATMENT effectiveness ,LEUKOCYTE count ,SOMATIC mutation ,GENETIC mutation ,RNA splicing - Abstract
The impact of clonal heterogeneity on disease behavior or drug response in acute myeloid leukemia remains poorly understood. Using a cohort of 2,829 patients, we identify features of clonality associated with clinical features and drug sensitivities. High variant allele frequency for 7 mutations (including NRAS and TET2) associate with dismal prognosis; elevated GATA2 variant allele frequency correlates with better outcomes. Clinical features such as white blood cell count and blast percentage correlate with the subclonal abundance of mutations such as TP53 and IDH1. Furthermore, patients with cohesin mutations occurring before NPM1, or transcription factor mutations occurring before splicing factor mutations, show shorter survival. Surprisingly, a branched pattern of clonal evolution is associated with superior clinical outcomes. Finally, several mutations (including NRAS and IDH1) predict drug sensitivity based on their subclonal abundance. Together, these results demonstrate the importance of assessing clonal heterogeneity with implications for prognosis and actionable biomarkers for therapy. Individual studies have been underpowered to draw clear associations between clonal heterogeneity and response to therapy in acute myeloid leukemia (AML). Here, the authors aggregate multiple AML cohorts and are able to correlate the clonal abundance of somatic mutations with clinical outcomes and drug sensitivity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
- Author
-
Azizi, Armon, Ediriwickrema, Asiri, Dutta, Ritika, Patel, Shyam A., Shomali, William, Medeiros, Bruno, Iberri, David, Gotlib, Jason, Mannis, Gabriel, Greenberg, Peter, Majeti, Ravindra, and Zhang, Tian
- Subjects
MYELODYSPLASTIC syndromes ,ACUTE myeloid leukemia ,BCL-2 proteins - Abstract
Treatment with hypomethylating agents (HMAs) azacitidine or decitabine is the current standard of care for high risk myelodysplastic syndromes (MDSs) but is associated with low rates of response. The limited number of treatment options for patients with high risk MDS highlights a need for new therapeutic options. Venetoclax is an inhibitor of the BCL-2 protein which, when combined with an HMA, has shown high response rates in unfit and previously untreated acute myeloid leukemia. We performed a retrospective study of high risk MDS patients receiving combination HMA plus venetoclax in order to determine their effectiveness in this context. We show that in our cohort, the combination results in high response rates but is associated with a high frequency of myelosuppression. These data highlight the efficacy of combination HMA plus venetoclax in high risk MDS, warranting further prospective evaluation in clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. A Dysregulated DNA Methylation Landscape Linked to Gene Expression in MLL-Rearranged AML.
- Author
-
Koldobskiy, Michael A., Abante, Jordi, Jenkinson, Garrett, Pujadas, Elisabet, Tetens, Ashley, Zhao, Feifei, Tryggvadottir, Rakel, Idrizi, Adrian, Reinisch, Andreas, Majeti, Ravindra, Goutsias, John, and Feinberg, Andrew P.
- Subjects
DNA methylation ,GENE expression ,ACUTE myeloid leukemia ,EPIGENETICS ,NUCLEOTIDE sequencing ,LEUKEMIA - Abstract
Translocations of the KMT2A (MLL) gene define a biologically distinct and clinically aggressive subtype of acute myeloid leukaemia (AML), marked by a characteristic gene expression profile and few cooperating mutations. Although dysregulation of the epigenetic landscape in this leukaemia is particularly interesting given the low mutation frequency, its comprehensive analysis using whole genome bisulphite sequencing (WGBS) has not been previously performed. Here we investigated epigenetic dysregulation in nine MLL-rearranged (MLL-r) AML samples by comparing them to six normal myeloid controls, using a computational method that encapsulates mean DNA methylation measurements along with analyses of methylation stochasticity. We discovered a dramatically altered epigenetic profile in MLL-r AML, associated with genome-wide hypomethylation and a markedly increased DNA methylation entropy reflecting an increasingly disordered epigenome. Methylation discordance mapped to key genes and regulatory elements that included bivalent promoters and active enhancers. Genes associated with significant changes in methylation stochasticity recapitulated known MLL-r AML expression signatures, suggesting a role for the altered epigenetic landscape in the transcriptional programme initiated by MLL translocations. Accordingly, we established statistically significant associations between discordances in methylation stochasticity and gene expression in MLL-r AML, thus providing a link between the altered epigenetic landscape and the phenotype. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. IL-6 blockade reverses bone marrow failure induced by human acute myeloid leukemia.
- Author
-
Zhang, Tian Yi, Dutta, Ritika, Benard, Brooks, Zhao, Feifei, Yin, Raymond, and Majeti, Ravindra
- Subjects
ACUTE myeloid leukemia ,BONE marrow ,ERYTHROCYTES ,HEMATOPOIESIS ,INTERLEUKIN-6 ,BONE marrow examination ,CELL differentiation - Abstract
Sometimes, crowding is not the problem: Bone marrow failure is a common and potentially deadly consequence of acute myeloid leukemia. Although traditional thinking holds that this bone marrow failure results from overcrowding, increasing evidence shows that it occurs even with low burden of disease that would not fill the bone marrow. Zhang et al. developed a mouse model that mimics the course of human disease and determined that acute myeloid leukemia cells produce a cytokine called interleukin-6, which interferes with red blood cell differentiation. In this mouse model, a blocking antibody targeting this cytokine treated the animals' anemia and improved their survival. Most patients with acute myeloid leukemia (AML) die from complications arising from cytopenias resulting from bone marrow (BM) failure. The common presumption among physicians is that AML-induced BM failure is primarily due to overcrowding, yet BM failure is observed even with low burden of disease. Here, we use large clinical datasets to show the lack of correlation between BM blast burden and degree of cytopenias at the time of diagnosis. We develop a splenectomized xenograft model to demonstrate that transplantation of human primary AML into immunocompromised mice recapitulates the human disease course by induction of BM failure via depletion of mouse hematopoietic stem and progenitor populations. Using unbiased approaches, we show that AML-elaborated IL-6 acts to block erythroid differentiation at the proerythroblast stage and that blocking antibodies against human IL-6 can improve AML-induced anemia and prolong overall survival, suggesting a potential therapeutic approach. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia.
- Author
-
Corces, M. Ryan, Chang, Howard Y., and Majeti, Ravindra
- Subjects
ACUTE myeloid leukemia ,MYELOID leukemia ,HEMATOPOIETIC stem cells - Abstract
Acute myeloid leukemia (AML) is an aggressive malignancy of the bone marrow characterized by an uncontrolled proliferation of undifferentiated myeloid lineage cells. Decades of research have demonstrated that AML evolves from the sequential acquisition of genetic alterations within a single lineage of hematopoietic cells. More recently, the advent of high-throughput sequencing has enabled the identification of a premalignant phase of AML termed preleukemia. Multiple studies have demonstrated that AML can arise from the accumulation of mutations within hematopoietic stem cells (HSCs). These HSCs have been termed "preleukemic HSCs" as they represent the evolutionary ancestors of the leukemia. Through examination of the biological and clinical characteristics of these preleukemic HSCs, this review aims to shed light on some of the unexplored questions in the field. We note that some of the material discussed is speculative in nature and is presented in order to motivate future work. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Biology and relevance of human acute myeloid leukemia stem cells.
- Author
-
Thomas, Daniel and Majeti, Ravindra
- Subjects
- *
ACUTE myeloid leukemia , *ACUTE myeloid leukemia treatment , *XENOGRAFTS , *CANCER chemotherapy , *EPIGENETICS , *PATIENTS - Abstract
Evidence of human acute myeloid leukemia stem cells (AML LSCs) was first reported nearly 2 decades ago through the identification of rare subpopulations of engrafting cells in xenotransplantation assays. These AML LSCs were shown to reside at the apex of a cellular hierarchy that initiates and maintains the disease, exhibiting properties of self-renewal, cell cycle quiescence, and chemoresistance. This cancer stem cell model offers an explanation for chemotherapy resistance and disease relapse and implies that approaches to treatment must eradicate LSCs for cure. More recently, a number of studies have both refined and expanded our understanding of LSCs and intrapatient heterogeneity in AML using improved xenotransplant models, genome-scale analyses, and experimental manipulation of primary patient cells. Here, we review these studies with a focus on the immunophenotype, biological properties, epigenetics, genetics, and clinical associations of human AML LSCs and discuss critical questions that need to be addressed in future research. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity.
- Author
-
Jonas, Brian A., Johnson, Carl, Gratzinger, Dita, and Majeti, Ravindra
- Subjects
ACUTE myeloid leukemia treatment ,XENOGRAFTS ,CANCER stem cells ,CELL populations ,PROGENITOR cells ,LABORATORY mice - Abstract
Acute myeloid leukemia (AML) is a heterogeneous group of aggressive bone marrow cancers arising from transformed hematopoietic stem and progenitor cells (HSPC). Therapy-related AML and MDS (t-AML/MDS) comprise a subset of AML cases occurring after exposure to alkylating chemotherapy and/or radiation and are associated with a very poor prognosis. Less is known about the pathogenesis and disease-initiating/leukemia stem cell (LSC) subpopulations of t-AML/MDS compared to their de novo counterparts. Here, we report the development of mouse models of t-AML/MDS. First, we modeled alkylator-induced t-AML/MDS by exposing wild type adult mice to N-ethyl-N-nitrosurea (ENU), resulting in several models of AML and MDS that have clinical and pathologic characteristics consistent with human t-AML/MDS including cytopenia, myelodysplasia, and shortened overall survival. These models were limited by their inability to transplant clinically aggressive disease. Second, we established three patient-derived xenograft models of human t-AML. These models led to rapidly fatal disease in recipient immunodeficient xenografted mice. LSC activity was identified in multiple HSPC subpopulations suggesting there is no canonical LSC immunophenotype in human t-AML. Overall, we report several new t-AML/MDS mouse models that could potentially be used to further define disease pathogenesis and test novel therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
11. Sticking It to the Niche: CD98 Mediates Critical Adhesive Signals in AML.
- Author
-
Reinisch, Andreas and Majeti, Ravindra
- Subjects
- *
ACUTE myeloid leukemia , *CD98 antigen , *CANCER cells , *CANCER stem cells , *CELL adhesion - Abstract
In this issue of Cancer Cell , Bajaj and colleagues report that CD98, a heterodimeric protein highly expressed in acute myeloid leukemia (AML) and largely dispensable for basal hematopoiesis, plays an important role in facilitating leukemia stem cell adhesion to bone marrow vasculature and is a potential therapeutic target in AML. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
12. Clonal evolution of pre-leukemic hematopoietic stem cells precedes human acute myeloid leukemia.
- Author
-
Majeti, Ravindra
- Abstract
Massively parallel DNA sequencing has uncovered recurrent mutations in many human cancers. In acute myeloid leukemia (AML), cancer genome/exome resequencing has identified numerous recurrently mutated genes with an average of 5 mutations in each case of de novo AML. In order for these multiple mutations to accumulate in a single lineage of cells, they are serially acquired in clones of self-renewing hematopoietic stem cells (HSC), termed pre-leukemic HSC. Isolation and characterization of pre-leukemic HSC have shown that their mutations are enriched in genes involved in regulating DNA methylation, chromatin modifications, and the cohesin complex. On the other hand, genes involved in regulating activated signaling are generally absent. Pre-leukemic HSC have been found to persist in clinical remission and may ultimately give rise to relapsed disease through the acquisition of novel mutations. Thus, pre-leukemic HSC may constitute a key cellular reservoir that must be eradicated for long-term cures. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
13. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.
- Author
-
Ryan Corces-Zimmerman, M., Wan-Jen Hong, Weissman, Irving L., Medeiros, Bruno C., and Majeti, Ravindra
- Subjects
ACUTE myeloid leukemia ,HEMATOPOIETIC stem cells ,BONE marrow cells ,CANCER chemotherapy ,CHROMATIN - Abstract
Cancer is widely characterized by the sequential acquisition of genetic lesions in a single lineage of cells. Our previous studies have shown that, in acute myeloid leukemia (AML), mutation acquisition occurs in functionally normal hematopoietic stem cells (HSCs). These preleukemic HSCs harbor some, but not all, of the mutations found in the leukemic cells. We report here the identification of patterns of mutation acquisition in human AML Our findings support a model in which mutations in "landscaping" genes, involved in global chromatin changes such as DNA methylation, histone modification, and chromatin looping, occur early in the evolution of AML, whereas mutations in "proliferative" genes occur late. Additionally, we analyze the persistence of preleukemic mutations in patients in remission and find CD34+ progenitor cells and various mature cells that harbor preleukemic mutations. These findings indicate that preleukemic HSCs can survive induction chemotherapy, identifying these cells as a reservoir for the reevolution of relapsed disease. Finally, through the study of several cases of relapsed AML, we demonstrate various evolutionary patterns for the generation of relapsed disease and show that some of these patterns are consistent with involvement of preleukemic HSCs. These findings provide key insights into the monitoring of minimal residual disease and the identification of therapeutic targets in human AML. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
14. Cyclin-Al represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen.
- Author
-
Ochsenreither, Sebastian, Majeti, Ravindra, Schmitt, Thomas, Stirewalt, Derek, Keilholz, Ulrich, Loeb, Keith R., Wood, Brent, Choi, Yongiae E., Bleakley, Marie, Warren, Edus H., Hudecek, Michael, Akatsuka, Yoshiki, Weissman, Irving L., and Greenberg, Philip D.
- Subjects
- *
CYCLINS , *ANTIGENS , *ACUTE myeloid leukemia , *T cells , *DENDRITIC cells , *OLIGOPEPTIDES , *EPITOPES , *HEMATOPOIETIC stem cells - Abstract
Targeted T-cell therapy is a potentially less toxic strategy than allogeneic stem cell transplantation for providing a cytotoxic antileukemic response to eliminate leukemic stem cells (LSCs) in acute myeloid leukemia (AML). However, this strategy requires identification of leukemia-associated antigens that are immunogenic and exhibit selective high expression in AML LSCs. Using microarray expression analysis of LSCs, hematopoietic cell subpopulations, and peripheral tissues to screen for candidate antigens, cyclin-A1 was identified as a candidate gene. Cyclin-A1 promotes cell proliferation and survival, has been shown to be leukemogenic in mice, is detected in LSCs of more than 50% of AML patients, and is minimally expressed in normal tissues with exception of testis. Using dendritic cells pulsed with a cyclin-A1 peptide library, we generated T cells against several cyclin-A1 oligopeptides. Two HLA A*0201 -restricted epitopes were further characterized, and specific CD8 T-cell clones recognized both peptide-pulsed target cells and the HLA A*0201 -positive AML line THP-1, which expresses cyclin-A1. Furthermore, cyclin-A1 -specific CD8 T cells lysed primary AML cells. Thus, cyclin-A1 is the first prototypic leukemia-testis-antigen to be expressed in AML LSCs. The pro-oncogenic activity, high expression levels, and multitude of immunogenic epitopes make it a viable target for pursuing T cell-based therapy approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
15. Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia.
- Author
-
Gentles, Andrew J., Plevritis, Sylvia K., Majeti, Ravindra, and Alizadeh, Ash A.
- Subjects
LEUKEMIA ,STEM cell research ,GENE expression ,ACUTE myeloid leukemia ,HEALTH outcome assessment ,MEDICAL genetics - Abstract
The article presents information on a retrospective study which identified a leukemic stem cell (LSC) gene expression signature and examined its relationship with clinical outcomes in acute myeloid leukemia (AML). Data collection was done at a U.S. medical center between April 2005 and July 2007. Main outcome measures included relationship of LSC-specific genes with overall, event-free and relapse-free survival and with therapeutic response, and identification of genes discriminating LSC-enriched populations from other subpopulations in AML tumors. A discussion on the research findings is detailed.
- Published
- 2010
- Full Text
- View/download PDF
16. Convergent epigenetic evolution drives relapse in acute myeloid leukemia.
- Author
-
Nuno, Kevin, Azizi, Armon, Koehnke, Thomas, Lareau, Caleb, Ediriwickrema, Asiri, Corces, M. Ryan, Satpathy, Ansuman T., and Majeti, Ravindra
- Subjects
- *
ACUTE myeloid leukemia , *CONVERGENT evolution , *EPIGENOMICS - Abstract
Relapse of acute myeloid leukemia (AML) is highly aggressive and often treatment refractory. We analyzed previously published AML relapse cohorts and found that 40% of relapses occur without changes in driver mutations, suggesting that non-genetic mechanisms drive relapse in a large proportion of cases. We therefore characterized epigenetic patterns of AML relapse using 26 matched diagnosis-relapse samples with ATAC-seq. This analysis identified a relapsespecific chromatin accessibility signature for mutationally stable AML, suggesting that AML undergoes epigenetic evolution at relapse independent of mutational changes. Analysis of leukemia stem cell (LSC) chromatin changes at relapse indicated that this leukemic compartment underwent significantly less epigenetic evolution than non-LSCs, while epigenetic changes in non-LSCs reflected overall evolution of the bulk leukemia. Finally, we used single-cell ATAC-seq paired with mitochondrial sequencing (mtscATAC) to map clones from diagnosis into relapse along with their epigenetic features. We found that distinct mitochondrially-defined clones exhibit more similar chromatin accessibility at relapse relative to diagnosis, demonstrating convergent epigenetic evolution in relapsed AML. These results demonstrate that epigenetic evolution is a feature of relapsed AML and that convergent epigenetic evolution can occur following treatment with induction chemotherap. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Clonal evolution of pre-leukemic hematopoietic stem cells in human acute myeloid leukemia.
- Author
-
Majeti, Ravindra
- Subjects
- *
HEMATOPOIETIC stem cells , *ACUTE myeloid leukemia , *HEALTH outcome assessment , *GENETIC mutation , *PROGENITOR cells , *DISEASE progression - Published
- 2014
- Full Text
- View/download PDF
18. 3053 – ENGINEERING SEQUENTIAL MUTATIONS INTO HUMAN HSPCS YIELDS AN AGGRESSIVE MYELOID MALIGNANCY ALLOWING FOR INTERROGATION OF PRELEUKEMIC TRANSFORMATION.
- Author
-
Collins, Cailin, Nakauchi, Yusuke, Koehnke, Thomas, Chavez, James, Choi, Suyoun, Sharma, Rajiv, Zhao, Feifei, and Majeti, Ravindra
- Subjects
- *
HUMAN biology , *HEMATOPOIETIC stem cells , *GENE expression , *ACUTE myeloid leukemia , *CORD blood - Abstract
Acute Myeloid Leukemia (AML) is an aggressive malignancy that develops as the result of stepwise accumulation of mutations in hematopoietic stem and progenitor cells (HSPCs). While multiple studies have demonstrated the ability of various combinations of mutations to promote leukemic transformation in mouse models, the majority of this work has studied concurrent alteration of driver genes, which may not accurately reflect human disease biology. To this end, we developed a model of myeloid transformation by sequentially introducing mutations into human HSPCs to study driver gene dependent and independent pathways in preleukemic transformation. Using CRISPR/Cas9-mediated gene disruption and AAV6-mediated homology directed repair (HDR) in human cord blood HSPCs, we developed a system for high-efficiency knockout of epigenetic modifiers DNMT3A or TET2 and subsequent expression of mutant signaling protein NRAS-G12D through a serial xenotransplantation approach. We found that the combination of either DNMT3A-KO or TET2-KO with NRAS-G12D in human HSPCs results in a rapidly fatal high-grade myeloid neoplasm. Moribund mice develop peripheral cytopenias, enlarged spleens, and have infiltration of human cells in bone marrow, spleen, and liver. Transformed cells have a monocytic immunophenotype (CD34-, CD33+, CD14 variable, CD16 variable) and can propagate disease in secondary transplants. Using this model, we demonstrate mutational synergy between TET2-KO and NRAS-G12D when compared with NRAS-G12D alone, whereas the same is not observed with DNMT3A-KO and NRAS-G12D. To our knowledge, this represents the first sequential model of preleukemic transformation in genetically engineered human HSPCs. Importantly, the sequential nature of our approach allows for interrogation of stepwise myeloid transformation, as well as studies with manipulation of the preleukemic phase of disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition.
- Author
-
Sinha, Subarna, Thomas, Daniel, Linda Yu, Gentles, Andrew J., Namyoung Jung, Corces-Zimmerman, M. Ryan, Chan, Steven M., Reinisch, Andreas, Feinberg, Andrew P., Dill, David L., and Majeti, Ravindra
- Subjects
- *
ACUTE myeloid leukemia , *DNA methylation , *CYTOSINE , *GENETIC mutation , *POLYCOMB group proteins - Abstract
Acute myeloid leukemia (AML) is associated with deregulation of DNA methylation; however, many cases do not bear mutations in known regulators of cytosine guanine dinucleotide (CpG) methylation. We found that mutations in WT1, IDH2, and CEBPA were strongly linked to DNA hypermethylation in AML using a novel integrative analysis of The Cancer Genome Atlas data based on Boolean implications, if-then rules that identify all individual CpG sites that are hypermethylated in the presence of a mutation. Introduction of mutant WT1 (WT1mut) into wild-type AML cells induced DNA hypermethylation, confirming mutant WT1 to be causally associated with DNA hypermethylation. Methylated genes in WT1mut primary patient samples were highly enriched for polycomb repressor complex 2 (PRC2) targets, implicating PRC2 dysregulation in WT1mut leukemogenesis. We found that PRC2 target genes were aberrantly repressed in WT1mut AML, and that expression of mutant WT1 in CD34+ cord blood cells induced myeloid differentiation block. Treatment of WT1mut AML cells with short hairpin RNA or pharmacologic PRC2/enhancer of zeste homolog 2 (EZH2) inhibitors promoted myeloid differentiation, suggesting EZH2 inhibitors may be active in this AML subtype. Our results highlight a strong association between mutant WT1 and DNA hypermethylation in AML and demonstrate that Boolean implications can be used to decipher mutation-specific methylation patterns that may lead to therapeutic insights. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
20. Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2)
- Author
-
Medeiros, Bruno C., Kohrt, Holbrook E., Arber, Daniel A., Bangs, Charles D., Cherry, Athena M., Majeti, Ravindra, Kogel, Karen E., Azar, Catherine A., Patel, Samit, and Alizadeh, Ash A.
- Subjects
- *
ACUTE myeloid leukemia , *IMMUNOPHENOTYPING , *CELL differentiation , *FLOW cytometry , *BLOOD diseases , *ANTIGENS , *NOSOLOGY - Abstract
Abstract: Immunophenotypic identification of myeloid specific antigens is an important diagnostic tool in the management of patients with acute myeloid leukemia (AML). These antigens allow determination of cell of origin and degree of differentiation of leukemia blasts. AML with inv(3)(q21q26.2)/t(3;3)(q21;q26.2) is a relatively rare subtype of AML. The immunophenotypic characteristics of inv(3) AML patients are somewhat limited. We identified 14 new cases of hematological disorders with increased myeloid blasts carrying inv(3)(q21q26.2)/t(3;3)(q21;q26.2). Also, we identified another 13 cases previously published in the literature, where the immunophenotype of inv(3)(q21q26.2) was documented. As a group, patients with AML with inv(3)(q21q26.2) had high levels of early myeloid (CD13, CD33, CD117 and MPO) and uncommitted markers (CD34, HLA-DR and CD56) and a high rate of monosomy 7 in addition to the inv(3)(q21q26.2). Differential karyotype and expression of certain antigens were noted in patients with de novo AML with inv(3)(q21q26.2) vs. those with inv(3)(q21q26.2)-containing blasts. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
21. Wilms' tumor 1 mutation drives DNA hypermethylation in AML and responds to EZH2-inhibitor.
- Author
-
Thomas, Daniel, Sinha, Subarna, Gentles, Andrew, Jung, Namyoung, Feinberg, Andrew, Dill, David, and Majeti, Ravindra
- Subjects
- *
NEPHROBLASTOMA , *GENETIC mutation , *DNA methylation , *CELLULAR signal transduction , *ACUTE myeloid leukemia , *CYTOSINE , *KARYOTYPES , *PATIENTS - Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.